Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU
25 mai 2021 09h00 HE
|
Auris Medical AG
Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical...
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
13 avr. 2021 07h45 HE
|
Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
29 janv. 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection
01 déc. 2020 09h00 HE
|
Auris Medical AG
Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001)Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection Hamilton, Bermuda, December...
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
20 nov. 2020 09h10 HE
|
Auris Medical AG
Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Launches Development of Drug-Free Nasal Spray for Protection against Airborne Pathogens and Allergens
08 sept. 2020 08h30 HE
|
Auris Medical AG
Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99%Creation of dedicated...